ATC code C08CA14 (WHO) PubChem CID 5282138 Molar mass 492.52 g/mol | CAS Number 132203-70-4 IUPHAR/BPS 7767 | |
 | ||
Trade names Atelec (アテレック), Cilacar AHFS/Drugs.com International Drug Names | ||
Cilidin cilnidipine calcium channel blocker
Cilnidipine (INN) is a calcium channel blocker. Cilnidipine is the novel calcium antagonist accompanied with -type and -type calcium channel blocking function. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved to come into market for the first time and used as antihypertensive in 1995. Unlike other calcium antagonists, Cilnidipine can act on the -type calcium channel in addition to acting on -type calcium channel like most other calcium antagonists. Cilnidipine is approved for use in Japan, China, India, Korea, and some European countries. Hypertension is the most common cardiovascular disease. Around 50 million individuals in the United States and 1 billion individuals worldwide are affected by hypertension
Contents
- Cilidin cilnidipine calcium channel blocker
- Medical uses
- Adverse effects
- Clinical Benefits
- Brand names
- References
Medical uses
Cilnidipine is used to manage hypertension. Due to its blocking action at N-type and L type calcium channel, cilnidipine dilates both arterioles and venules, reducing the pressure in the capillary bed.
Adverse effects
Peripheral edema, a common side effect of the use of amlodipine, was found to be reduced when patients were shifted to cilnidipine (citation needed).
Clinical Benefits
Cilnidipine has enhanced lipophilicity leading to prolonged antihypertensive effect correlated with occupancy of the binding site. In 24-hour clinical assessment, once-daily administration of cilnidipine produced blood pressuree reduction for 24-hour period (citation needed). The inhibitory effect on the N-type Ca2+ channel may bestow an additional clinical advantage for the treatment of hypertension, such as suppression of reflex tachycardia (citation needed).
As catecholamines induce platelet activation via α2-receptor on platelet membrane, decrease in norepinephrine level by cilnidipine causes attenuation of platelet activation.
Brand names
In Bangladesh it is marketed by The Acme Laboratories Ltd. under the brand name Duocard, available as both 5 mg & 10 mg and Opsonin Pharma Ltd. Under the brand name Cildip and is available in 5 mg and 10 mg tablets. In India it is marketed by JBCPL under the brand name Cilacar and is available in 5 mg, 10 mg, 20 mg and other combinations. In Japan it is marketed BY Ajinomoto Pharmaceuticals Co., Ltd.under the brand name Atelec. In the United States it is available in different brands whose central ingredients are Cilnidipine, including Atelec and Cilacar.